

This Page Is Inserted by IFW Operations  
and is not a part of the Official Record

## **BEST AVAILABLE IMAGES**


Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

**IMAGES ARE BEST AVAILABLE COPY.**

**As rescanning documents *will not* correct images,  
please do not report the images to the  
Image Problem Mailbox.**



Atty.  
Dkt. No.

M#

Client Ref.

037003-0280609

2000-30-0154A

**INFORMATION DISCLOSURE STATEMENT  
BY APPLICANT**

Applicant: Grillo-Lopez

Appln. No.: 09/840,872

Filing Date: April 25, 2001

Examiner: Gary B. Nickol

Group Art Unit: 1642

Date: September 25, 2003

Page

1

6

**RECEIVED**  
OCT 01 2003  
TECH CENTER 1600/2900

**U.S. PATENT DOCUMENTS**

Examiner's Initials*		Document Number	Date MM/YYYY	Name (Family Name of First Inventor)	Class	Sub Class	Filing Date (if appropriate)
GW	AR	4,348,376	09/1982	Goldenberg	424	1	
	BR	4,454,106	06/1984	Gansow, et al.	424	1.1	
	CR	4,460,559	07/1984	Goldenberg	424	1.1	
	DR	4,472,509	09/1984	Gansow, et al.	436	548	
	ER	4,665,077	05/1987	Stringfellow, et al.	514	269	
	FR	4,816,567	03/1989	Cabilly, et al.	530	387	
	GR	4,831,175	05/1989	Gansow, et al.	558	17	
	HR	5,114,721	05/1992	Cohen, et al.	424	534	
	IR	5,116,964	05/1992	Capon, et al.	536	27	
	JR	5,182,107	01/1993	Friden	424	85.91	
	KR	5,500,362	03/1996	Robinson, et al.	435	7.23	
	LR	5,595,721	01/1997	Kaminski, et al.	424	1.49	
	MR	5,674,492	10/1997	Armitage, et al.	424	144.1	
	NR	5,677,180	10/1997	Robinson, et al.	435	328	
	OR	5,693,780	12/1997	Newman, et al.	536	23.53	
	PR	5,736,137	04/1998	Anderson, et al.	424	133.1	
	QR	5,747,037	05/1998	Noelle, et al.	424	154.1	
	RR	5,776,456	07/1998	Anderson, et al.	424	133.1	
	SR	5,801,227	09/1998	Fanslow, III et al.	530	388.73	
	TR	5,821,337	10/1998	Carter, et al.	530	387.3	
	UR	5,833,987	11/1998	Noelle, et al.	424	154.1	
	VR	5,843,398	12/1998	Kaminski, et al.	424	1.49	
	WR	5,843,439	12/1998	Anderson, et al.	424	133.1	
	XR	5,874,082	02/1999	de Boer	424	153.1	
	YR	5,874,085	02/1999	Mond, et al.	424	195.11	
	ZR	5,876,718	03/1999	Noelle, et al.	424	154.1	
	AAR	5,716,614	02/1998	Katz, et al.	424	94.3	
	BBR	6,001,358	12/1999	Black, et al.	424	154.1	
	CCR	6,183,744	02/2001	Goldenberg	424	131.1	
	DDR	6,306,393	10/2001	Goldenberg	424	141.1	

**FOREIGN PATENT DOCUMENTS**

		Document Number	Date MM/YYYY	Country	Inventor Name	English Abstract		Translation Readily Available	
						Enclosed	No	Enclose	No
GW	EER	0 340 109 B1	05/1997	EP	Steinman, et al.				
	FFR	0 404,097 B1	09/1996	EP	Bosslet, et al.				
	GGR	0 555 880 A2	08/1993	EP	Aruffo, et al.				
	HHR	0 555 880 A3	08/1993	EP	Aruffo, et al.				

GN	IIR	WO 90/081	07/1990	WO	Reinherz, et al.				
	JJR	WO 90/11294	10/1990	WO	Howell, et al.				
	KKR	WO 91/01133	02/1991	WO	Goldstein, et al.				
	LLR	WO 93/11161	06/1993	WO	Whitlow, et al.				
SEP 26 2003	MMR	WO 94/11026	05/1994	WO	Anderson, et al.				
	NNR	WO 95/06666	03/1995	WO	Noelle, et al.				
	OODR	WO 95/17202	06/1995	WO	Armitage, et al.				

RECEIVE

OCT 01 2003

TECH CENTER 1600/2900

OTHER (Including in this order Author, Title, Periodical Name, Date, Pertinent Pages, etc.)



GN	PPR	Abrey <i>et al.</i> , Combination chemotherapy in primary central nervous system lymphoma," (abstract) <u>Proc. Am. Soc. Clin. Onc.</u> (1999)							
	QQR	Abrey <i>et al.</i> , Long-term survival in primary CNS lymphoma, <u>J. Clin. Oncol.</u> 16: 859-63 (1998)							
	RRR	Armitage <i>et al.</i> , Molecular and biological characterization of a murine ligand for CD40, <u>Nature</u> 357:80-82 (1992)							
	SSR	Behr <i>et al.</i> , Low-versus high-dose radioimmunotherapy with humanized anti-CD22 or chimeric anti-CD20 antibodies in a broad spectrum of B cell-associated malignancies, <u>Clin. Cancer Res.</u> 5: 3304s-14s (1999)							
	TTR	Bejcek <i>et al.</i> , Development and characterization of three recombinant single chain antibody fragments (scFvs) directed against the CD19 antigen, <u>Cancer Res.</u> 55: 2346-51 (1995)							
	UUR	Benoit <i>et al.</i> , Increased inhibition of proliferation of human B cell lymphomas following ligation of CD40, and either CD19, CD20, CD95 or surface immunoglobulin, <u>Immunopharmacology</u> 35: 129-139 (1996)							
	VVR	Berinstein <i>et al.</i> , Association of serum rituximab (IDEC-C2B8) concentration and anti-tumor response in the treatment of recurrent low-grade or follicular non-Hodgkin's lymphoma, <u>Ann. Oncol.</u> 9: 995-1001 (1998)							
	WWR	Blay <i>et al.</i> , High-dose methotrexate for the treatment of primary cerebral lymphomas: Analysis of survival and late neurologic toxicity in a retrospective series, <u>J. Clin. Oncol.</u> 16: 864-871 (1998)							
	XXR	Bolognesi <i>et al.</i> , Evaluation of immunotoxins containing single-chain ribosome-inactivating proteins and an anti-CD22 monoclonal antibody (OM124): <i>in vitro</i> and <i>in vivo</i> studies, <u>Br. J. Haematol.</u> 101: 179-88 (1998)							
	YYR	Capon <i>et al.</i> , Designing CD4 immunoadhesins for AIDS therapy, <u>Nature</u> 337: 525-531 (1989)							
	ZZR	Chamberlain <i>et al.</i> , Primary central nervous system lymphoma: a role for adjuvant chemotherapy, <u>J. Neuro. Oncol.</u> 14: 271-275 (1992)							
	AAAR	Cheng <i>et al.</i> , Systemic chemotherapy alone for patients with non-acquired immunodeficiency syndrome-related central nervous system lymphoma, <u>Cancer</u> 82: 1946-51 (1998)							
	BBBR	Clodi <i>et al.</i> , Unbalanced expression of Fas and CD40 in mantle cell lymphoma, <u>Brit. J. Haematol.</u> 103: 217-9 (1998)							
	CCCR	Clynes <i>et al.</i> , Fc receptors are required in passive and active immunity to melanoma, <u>PNAS (USA)</u> 95:652-656 (1998)							
	DDDR	Coiffier <i>et al.</i> , Rituximab (anti-CD20 monoclonal antibody) for the treatment of patients with relapsing or refractory aggressive lymphoma: A multicenter phase II study, <u>Blood</u> 92: 1927-1932 (1998)							
	EEER	Czuczman <i>et al.</i> , Treatment of patients with low-grade B-cell lymphoma with the combinations of chimeric anti-CD20 monoclonal antibody and CHOP chemotherapy, <u>J. Clin. Oncol.</u> 17: 268-76 (1999)							
	FFFR	DeAngelis <i>et al.</i> , "Primary Central Nervous System Lymphoma," IN <u>CANCER: PRINCIPLES &amp; PRACTICE OF ONCOLOGY</u> 2233-2242 (DeVita <i>et al.</i> , eds. 1997).							
	GGGR	Deguchi <i>et al.</i> , Retention of biologic activity of human epidermal growth factor following conjugation of a blood-brain barrier drug delivery vector via an extended poly(ethylene glycol) linker, <u>Bioconjug. Chem.</u> 10: 32-37 (1999)							
	HHHR	Endo, <u>Gan To Kagaku Ryoho</u> 26: 744-748 (1999)							

IIIR	Finé <i>et al.</i> , Primary central nervous system lymphoma, <u>Ann. Intern. Med.</u> 119: 1093-1104 (1993)				
IIJR	Flavell <i>et al.</i> , Therapy of human B-cell lymphoma bearing SCID mice is more effective with anti-CD19- and anti-CD38-saporin immunotoxins used in combination than with either immunotoxin used alone, <u>Int. J. Cancer</u> 62: 337-44 (1995)				
KKRR	Freilich <i>et al.</i> , Chemotherapy without radiation therapy as initial. Treatment for primary CNS lymphoma in older patients, <u>Neurology</u> 46: 435-439 (1996)				
LLLR	Funakoshi <i>et al.</i> , Inhibition of human B-cell lymphoma growth by CD40 stimulation, <u>Blood</u> 83: 2787-2794 (1994)				
MMMR	Funakoshi <i>et al.</i> , Differential in vitro and in vivo antitumor effects mediated by anti-CD40 and anti-CD20 monoclonal antibodies against human B-cell lymphomas, <u>J. Immunother. Emphasis Tumor Immunol.</u> 19: 93-101 (1996)				
NNNR	Ghetie <i>et al.</i> , Anti-CD19 antibodies inhibit the function of the P-gp pump in multidrug-resistant B lymphoma cells, <u>Clin. Cancer Res.</u> 5: 3920-7 (1999)				
OOOR	Green <i>et al.</i> , Evidence for a continued requirement for CD40/CD40 ligand (CD154) interactions in the progression of LP-BM5 retrovirus-induced murine AIDS, <u>Virology</u> 241: 260-268 (1998)				
PPPR	Gruss <i>et al.</i> , CD40/CD40 ligand interactions in normal, reactive and malignant lympho-hematopoietic tissues, <u>Leuk. Lymphoma</u> 24: 393-422 (1997)				
QQQR	Hekman <i>et al.</i> , Initial experience with treatment of human B cell lymphoma with anti-CD19 monoclonal antibody <u>Cancer Immunol. Immunother.</u> 32:364-372 (1991)				
RRRR	Herrlinger <i>et al.</i> , Intrathecal therapy of leptomeningeal CEM T-cell lymphoma in nude rats with anti-CD7 ricin toxin A chain immunotoxin, <u>J. Neurooncol.</u> 40: 1-9 (1998)				
SSSR	Hollenbaugh <i>et al.</i> , The human T cell antigen gp39, a member of the TNF gene family, is a ligand for the CD40 receptor: expression of a soluble form of gp39 with B cell co-stimulatory activity, <u>EMBO J.</u> 11:4313-4321 (1992)				
TTTR	Hollinger <i>et al.</i> , "Diabodies": small bivalent and bispecific antibody fragments, <u>Proc. Natl. Acad. Sci. USA</u> , 90:6444-6448 (1993).				
UUUR	Huwylar <i>et al.</i> , Brain drug delivery of small molecules using immunoliposomes, <u>Proc. Nat'l Acad. Sci. USA</u> 93: 14164-14169 (1996)				
VVVR	Illidge <i>et al.</i> , The importance of antibody-specificity in determining successful radioimmunotherapy of B-cell lymphoma, <u>Blood</u> 94: 233-43 (1999)				
WWWR	Janeway, Immunotherapy by peptides, <u>Nature</u> , 341: 482 (1989)				
XXXR	Johnson <i>et al.</i> , Isolated follicular lymphoma cells are resistant to apoptosis and can be grown in vitro in the CD40/stromal cell system, <u>Blood</u> 82: 1848-1857 (1993)				
YYYY	Kiesel <i>et al.</i> , Removal of cells from a malignant B-cell line from bone marrow with immunomagnetic beads and with complement and immunoglobulin switch variant mediated cytolysis, <u>Leukemia Research</u> 11, 12: 1119 (1987)				
ZZZR	Kramer <i>et al.</i> , Tc-99m LL-2 Fab' monoclonal antibody imaging in acquired immune deficiency syndrome-related lymphoma, <u>Cancer</u> 80: 2469-2477 (1997)				
AAAAR	Kroll <i>et al.</i> , Outwitting the blood-brain barrier for therapeutic purposes: Osmotic opening and other means, <u>Neurosurgery</u> 42: 1083-99 (1998)				
BBBBR	Ledbetter <i>et al.</i> , Agonistic and antagonistic properties of CD40 mAb G28-5 are dependent on binding valency, <u>Circ. Shock</u> 44: 67-72 (1994)				

RECEIVED

OCT 01 2003

TECH CENTER 1600/2900

	CCCCR	Lederman <i>et al.</i> , Identification of a novel surface protein on activated CD4+ T cells that induces contact-dependent B cell differentiation (Help), <u>J. Exp. Med.</u> 175: 1091-1101 (1992)			
	DDDDR	Leget <i>et al.</i> , Use of rituximab, the new FDA-approved antibody, <u>Curr. Opin. Oncol.</u> 10: 548-551 (1998)			
	EEER	Lesser <i>et al.</i> , The chemotherapy of adult primary brain tumor, <u>Cancer Treat. Rev.</u> 19: 261-281 (1993)			
	FFFFR	Li <i>et al.</i> , Pharmacokinetics and biodistribution of radioimmunoconjugates of anti-CD19 antibody and single-chain Fv for treatment of human B-cell malignancy, <u>Cancer Immunol. Immunother.</u> 47: 121-30 (1998)			
	GGGGR	Lieberman <i>et al.</i> , Convection-enhanced distribution of large molecules in gray matter during interstitial drug infusion, <u>J. Neurosurg.</u> 82: 1021-1029 (1995)			
	HHHHR	Linsley <i>et al.</i> , Binding of the B cell activation antigen B7 to CD28 costimulates T cell proliferation and interleukin 2 mRNA accumulation, <u>J. Exp. Med.</u> 1783: 721-730 (1991)			
	IIIR	Maloney <i>et al.</i> , IDEC-C2B8 (Rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin's lymphoma, <u>Blood</u> 90: 2188-2195 (1997)			
	JJJJR	Mansfield <i>et al.</i> , Characterization of RFB4-pseudomonas exotoxin A immunotoxins targeted to CD22 on B-cell malignancies, <u>Bioconjug. Chem.</u> 7: 557-63 (1996)			
	KKKKR	Mason <i>et al.</i> , <sup>111</sup> Indium-diethylenetriamine pentaacetic acid cerebrospinal fluid flow studies predict distributin of intrathecally administered chemotherapy and outcome in patients with leptomeningeal metastases, <u>Neurology</u> 50: 438-444 (1998)			
	LLLLR	McLaughlin <i>et al.</i> , Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: Half of patients respond to a four-dose treatment program, <u>J. Clin. Oncol.</u> 16: 2825-2833 (1998)			
	MMMMR	McLaughlin <i>et al.</i> , Clinical status and opitimal use of rituximab for B-cell lymphomas, <u>Oncology (Huntingt)</u> 12: 1763-1777 (1998)			
	NNNNR	Monjour <i>et al.</i> , Lymphomes malins non Hodgkiniens primitifs du système nerveux central, <u>Rev. Neurol. (Paris)</u> 148: 589-600 (1992)			
	OOOOR	Morrison <i>et al.</i> , Genetically engineered antibody molecules, <u>Adv. Immunol.</u> 44: 65-92 (1988)			
	PPPPR	Morrison <i>et al.</i> , Chimeric human antibody molecules: Mouse antigen-binding domains with human constant region domains, <u>Proc. Natl. Acad. Sci. USA</u> , 81:6851-6855 (1984)			
	QQQQR	Murphy <i>et al.</i> , Antibodies to CD40 prevent Epstein-Barr virus-mediated human B-cell lymphomagenesis in severe combined immune deficient mice given human peripheral blood lymphocytes, <u>Blood</u> 86: 1946-1953 (1995)			
	RRRRR	Nguyen <i>et al.</i> , IDEC-C2B8 anti-CD20 (Rituximab) immunotherapy in patients with low-grade non-Hodgkin's lymphoma and lymphoproliferative disorders: evaluation of response on 48 patients, <u>Eur. J. Haematol.</u> 62: 76-82 (1999)			
	SSSSR	Offner <i>et al.</i> , T Cell receptor peptid th rapy triggers autoregulation of experimental encephalomyelitis, <u>Science</u> 251: 430-432 (1991)			
	TTTTTR	O'Neill <i>et al.</i> , Primary central nervous system non-Hodgkin's lymphoma: Survival advantages with combined initial therapy?, <u>Int'l J. Radiation Oncol. Biol. Phys.</u> 33: 663-673 (1995)			


RECEIVED

TECH CENTER 1800/2900  
OCT 01 2003

UUUUR	Orłowski, Hodgkin's disease with leptomeningeal involvement, <u>Cancer</u> 53: 1833-1835 (1984)				
VVVVR	Padlan, A possible procedure for reducing the immunogenicity of antibody variable domains while preserving their ligand-binding properties, <u>Molec. Immun.</u> 28: 489-498 (1991)				
WWWWR	Padlan, Anatomy of the antibody molecule, <u>Molec. Immun.</u> 31: 169-217 (1994)				
XXXXR	Partridge <i>et al.</i> , Combined use of carboxyl-directed protein pegylation and vector-mediated blood-brain barrier drug delivery system optimizes brain uptake of brain-derived neurotrophic factor following intravenous administration, <u>Pharm. Res.</u> 15: 576-82 (1998)				
YYYYR	Pastan <i>et al.</i> , Intrathecal administration of single-chain immunotoxin, LMB-7 [B3(Fv)-PE38], produces cures of carcinomatous meningitis in a rat model, <u>Proc. Nat'l Acad. Sci. USA</u> 92: 2765-2769 (1995)				
ZZZZR	Perez-Jaffe <i>et al.</i> , Cerebral spinal fluid involvement by Hodgkin's disease diagnosed by CSF cytology and immunocytochemistry, <u>Diagn. Cytopathol.</u> 20:219-223 (1999)				
AAAAAR	Piro <i>et al.</i> , Extended Rituximab (anti-CD20 monoclonal antibody) therapy for relapsed or refractory low-grade or follicular non-Hodgkin's lymphoma, <u>Ann. Oncol.</u> 10: 655-61 (1999)				
BBBBBR	Press <i>et al.</i> , Monoclonal antibody 1F2 (Anti-CD20) serotherapy of human B cell lymphomas, <u>Blood</u> 69: 584-591 (1987)				
CCCCCR	Ravetch and Kinet, Fc receptors, <u>Annu. Rev. Immunol</u> 9:457-92 (1991)				
DDDDDR	Reni <i>et al.</i> , Therapeutic management of primary central nervous system lymphoma in immunocompetent patients: Results of a critical review of the literature, <u>Ann. Oncol.</u> 8: 227-234 (1997)				
EEEEER	Sandor <i>et al.</i> , Phase II trial of chemotherapy alone for primary CNS and intraocular lymphoma, <u>J. Clin. Oncol.</u> 16: 3000-3006 (1998)				
FFFFFR	Schabet <i>et al.</i> , Diagnose und therapie der meningosis neoplastica, <u>Nervenarzt</u> 63: 317-27 (1992)				
GGGGGR	Stamenkovic <i>et al.</i> , A B-lymphocyte activation molecule related to the nerve growth factor receptor and induced by cytokines in carcinomas, <u>EMBO J.</u> 8: 1403-1410 (1989)				
HHHHHR	Stone <i>et al.</i> , A phase I study of bolus versus continuous infusion of the anti-CD19 immunotoxin, IgG-HD37-dgA, in patients with B-cell lymphoma, <u>Blood</u> 88: 1188-97 (1996)				
IIIIIR	Strauchen <i>et al.</i> , Chemotherapy in the management of intraocular lymphoma, <u>Cancer</u> 63: 1918-21 (1989)				
JJJJJR	Tutt <i>et al.</i> , Monoclonal antibody therapy of B cell lymphoma: Signaling activity on tumor cells appears more important than recruitment of effectors, <u>J. Immunol.</u> 161: 3176-3185 (1998)				
KKKKKR	Valentine <i>et al.</i> , B3.9 Structure and function of the B-cell specific 35-37 kDa CD20 protein, In: <u>Leukocyte Typing III</u> (McMichael, Ed., p. 440, Oxford University Press (1987)				
LLLLLR	Valle <i>et al.</i> , Activation of human B lymphocytes through CD40 and interleukin 4, <u>Eur. J. Immunol.</u> 19: 1463-1467 (1989)				
MMMMMR	Valluri <i>et al.</i> , Combination treatment of intraocular lymphoma, <u>Retina</u> 15: 125-9 (1995)				

RECEIVED

OCT 01 2003  
TECH CENTER 1600/2900

GN	NNNNNR	van Besien <i>et al.</i> , Risk factors, treatment, and outcome of central nervous system recurrence in adults with intermediate-grade and immunoblastic lymphoma, <u>Blood</u> 91: 1178-1184 (1998)				
	OOOOOR	Verhoeven <i>et al.</i> , Reshaping human antibodies: Grafting an antilysozyme activity, <u>Science</u> 239: 1534-1536 (1988)				
	PPPPR	Vlasveld <i>et al.</i> , Treatment of low-grade non-Hodgkin's lymphoma with continuous infusion of low-dose recombinant interleukin-2 in combination with the B-cell-specific monoclonal antibody CLB-CD19, <u>Cancer Immunol. Immunother.</u> 40:37-47(1995)				
	QQQQQR	Wang <i>et al.</i> , Induction of bcl-x by CD40 engagement rescues slg-induced apoptosis in murine B cells, <u>J. Immunol.</u> 155: 3722-5 (1995)				
	RRRRRR	White <i>et al.</i> , Anti-CD20 monoclonal antibodies as novel treatments for non-Hodgkin's lymphoma, <u>Pharm. Sci. Technol. Today</u> 2: 95-101 (1999)				
	SSSSSR	Wu <i>et al.</i> , Pharmacokinetics and blood-brain barrier transport of an anti-transferrin receptor monoclonal antibody (OX26) in rats after chronic treatment with the antibody, <u>Drug. Metabol. Dispos.</u> 26: 937-9 (1998)				
	TTTTTR	Youle, Immunotoxins for central nervous system malignancy, <u>Semin. Cancer Biol.</u> 7: 65-70 (1996)				
	UUUUUR					
	VVVVVR					
Examiner		Date Considered: 12/10/03				
*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.						

RECEIVED

OCT 01 2003

TECH CENTER 1600/2900